Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 12/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262345 | 0.93 | PDE5A (0.43) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL5262024 | 0.85 | PDE5A (0.42) | ADORA2BADORA2AADORA1ADORA3PDE1A | |
| SCHEMBL5827290 | 0.82 | ADORA1 (0.58) | ADORA2BADORA2AADORA1PDE1APDE1B | |
| SCHEMBL5830586 | 0.81 | PDE5A (0.59) | PDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6305525 | 0.81 | ADORA2B (0.55) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL5830233 | 0.80 | PDE5A (0.52) | ADORA1ADORA3PDE1APDE1BPDE1C | |
| SCHEMBL5263935 | 0.79 | PDE5A (0.41) | PDE5A | |
| SCHEMBL5260190 | 0.78 | PDE5A (0.54) | PDE1APDE1BPDE1CPDE5A | |
| SCHEMBL5262563 | 0.77 | ADORA2B (0.52) | ADORA2BADORA2AADORA1ADORA3PDE1A | |
| SCHEMBL7016108 | 0.77 | PDE5A (0.41) | ADORA2BADORA2AADORA1PDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307458-B1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL LAB (ES) | 2007-10-03 | — | — | EP | disclosed |
| US-7060824-B2 | Pyrrolotriazolopyrimidinone derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-06-13 | — | — | US | disclosed |
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | VIDAL JUAN BERNAT (ES) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | PDE5A, PDE3A, PDE2A | ADORA2B 1014/4885ADORA2A 847/4885ADORA1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.